0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, COVID-19, FDA ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) today announced it received guidance from the U.S Food & Drug Administration regarding the impact of COVID-19 on its Phase III clinical trial for osteoarthritis of the knee ("OAK"). The COVID-19 health emergency has impacted clinical trials, with more than 1,000 studies suspended as...
Read Full StoryRelated
, 5h
0
